Stockholm Stock Exchange.
Stockholm Stock Exchange shows up good risk appetite as the market returned after a long weekend. Blue Chip index rises by the commodities sector in the lead, a development which is in line with European exchanges. On the company front, rushing Probi after acquisitions and Precise Biometrics is rising in a number of updates.
SIX General Index was at 14:17 1.2 percent higher at 469 while the OMXS30 was 1.6 percent higher at 1.366. Sales amounted to SEK 7.1 billion on the Stockholm Stock Exchange. Trade also occurs in other venues such as Bats, Chi-X and Turquoise.
The market melts the American Governor Janet Yellens speech Monday evening, which in principle rules out a rate hike in June, according to CNBC.
In Europe, London, Paris and Frankfurt up by 0.4, 1.2, and 1.7 per cent. Trading takes place with the support of strong macro data and rising oil prices.
GDP for the eurozone rose by an upwardly revised 1.7 percent annual rate in the first quarter. The market had expected that GDP would remain at the preliminary level of 1.5 percent. Even on a German industrial production was stronger than expected in April.
Oil prices show a positive trend during Tuesday trading and both Brent and WTI oil recorded over 50 dollars a barrel. Among the Swedish oil companies rises Lundin Petroleum with 4.5 percent, 3.2 percent and Enquest Africa Oil 1.6 percent.
Continuing on the commodity side rises Boliden 2.6 percent and Lundin Mining 3.9 percent. Although the workshop was strong. Atlas Copco rose by 3.0 percent and Alfa Laval 2.3 percent.
Precise Biometrics has signed a license agreement with EOSMEM for the company’s algorithm solution in mobile devices, BioMatch Mobile. While the company states that the algorithm integrated into a smartphone and a notebook in the two previous collaborations. Shares rise 11 percent.
Probiotikabolaget Probi an asset acquisition of US Nutraceutix. The preliminary cash consideration amounting to the equivalent of 873 million kronor in cash and debt free basis.
The acquisition was financed partly through a new share issue of SEK 600 million. The acquisition will Probi to more than triple its market share in the North American market. The share rushes 21 percent.
The pharmaceutical company Sobi announced that it launched the drug Alprolix, the bleeding disorder hemophilia B, in Germany. The drug received marketing approval in the EU in mid-May. Shares rose 3.0 percent.
Sensys Gatso has through its partner RECK received a first order from the Latvian Traffic Authority regarding road safety systems in the country. The contract will provide Sensys Gatso Group three orders with a total value of EUR 2.5 million. The share increased 4.6 percent.
Nordea lowers recommendation for SAS to keep from previous purchases. The price target is pulled while down to 23 crowns, from the previous 28 crowns. Its shares are down 0.4 percent to 22.50 crowns.
No comments:
Post a Comment